117 results about "Gout patient" patented technology

The invention discloses a domestic hyperuricemia and gout patient management system and a management method therefor, relates to a health management system, and aims to solve the shortcomings existing in the existing conventional health management system. The invention provides the domestic hyperuricemia and gout patient management system, and the management system is characterized by comprising a detection instrument, a patient client, a database, a central processor and a doctor client. The domestic hyperuricemia and gout patient management system has the beneficial effects that the shortcomings of insufficiency of private doctors and expensive payment cost are overcame, so that the management system is suitable for doctors in many medical institutions for managing the hyperuricemia and gout patients; and the time of the doctors is saved, and the efficiency of the doctors is improved as well.

The invention discloses a traditional Chinese medicine composition with an efficacy on lowering uric acid, and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from 20-80 parts of poria cocos, 20-60 parts of coix seed, 5-20 parts of fructus gardeniae, 5-20 parts of peach kernel, 5-20 parts of fructus chaenomelis, 5-15 parts of rhizoma polygonati, 5-15 parts of herba lophatheri, 5-15 parts of licorice root, 2-20 parts of fructus lycii, 30-90 parts of radix puerariae, 20-60 parts of folium mori and 2-15 parts of radix ginseng. The compositiondisclosed by the invention has a scientific and reasonable formula, common medical and edible raw materials are selected, and the composition is proved to own an obvious uric acid lowering efficacy through an animal pharmacodynamic test and a clinical test, is safe and reliable, does not have toxic or side effect and is suitable for gout patients and high uric acid crowds to eat for a long time.

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

The invention particularly relates to a xanthine oxidase inhibitory peptide. The amino acid sequence of the xanthine oxidase inhibitory peptide is Glu-Glu-Ala-Lys (EEAK). The IC50 value of the tetrapeptide EEAK on xanthine oxidase inhibitory activity is 173.00+ / -0.06 [mu]M, the tetrapeptide EEAK has a continuous and stable inhibitory effect on xanthine oxidase, and the tetrapeptide EEAK has the outstanding advantages of safety, no toxic or side effect, easiness in absorption, industrialization and the like. The active tetrapeptide EEAK or the derivative thereof can be used for preparing gout treatment / prevention medicines or used as a functional food additive for long-term treatment and health care of gout patients, and has a wide application prospect and very important significance.

The invention relates to composite superfine powder for preventing and treating gout and hyperuricemia and a preparation method thereof and belongs to the technical field of traditional Chinese medicines. The composite superfine powder for preventing and treating gout and hyperuricemia is prepared by using the following raw materials in parts by weight: 1-3 parts of Dendrobium nobile, 1-3 parts of Dendrobium chrysanthum, 1-3 parts of gordon euryale seed, 1-3 parts of coix seed, 1-3 parts of kudzuvine root, 1-3 parts of lotus leaf and 1-3 parts of cinnamon. Since the composite superfine powder consists of Dendrobium nobile which is an endangered rare precious traditional Chinese medicinal material and raw materials which are not only food but also are medicines published by the Ministry of Health in 2002, are prepared by adopting an innovative process and does not have any toxic and side effect. After the composite superfine powder is orally taken by clinical patients, the blood uric acid content of patients who suffer from gout can be effectively reduced, the pain is relieved, the urine is alkalized, the metabolism is recovered and improved, and the applicability is wide.

The invention relates to a pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia. The pharmaceutical composition comprises the following components in parts by weight: 7-15 parts of fringed pink, 5-10 parts of radix clematidis and 5-13 parts of large-leaved gentian. The invention provides the pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia, and the pharmaceutical composition can lower blood uric acid content of gout patients, alleviate pain, prevent uric acid from rising and restore and improve the metabolism function of the patients and has no toxic and side effects.

The invention discloses bath liquid with an efficacy of alleviating gouty arthritis. The bath liquid is prepared from sodium bicarbonate thermal spring water and eight wild Chinese herbal medicines including Herba Lycopodii, Herba Blumeae Balsamiferae, Herba Bidentis Bipinnatae, Radix Ilicis Pubescentis and the like. The bath liquid can be used for foot bath or body bath of gout patients and is capable of well alleviating gouty arthritis and avoiding liver-kidney injuries caused by medicines.

The invention discloses health care tea capable of reducing uric acid, which consists of the following components in parts by weight: 48-52 parts of sun euphorbia herb, 48-52 parts of root of eggplant, 38-42 parts of rhizoma smilacis glabrae, 38-42 parts of sevenlobed yam rhizome, 38-42 parts of herba lysimachiae, 38-42 parts of semen coicis, 38-42 parts of achyranthes root, 48-52 parts of fructus lycii, 38-42 parts of pericarpium citri reticulatae viride, 38-42 parts of pericarpium citri reticulatae, 38-42 parts of radix salviae miltiorrhizae and 48-52 parts of liquorice. The health care tea has the effects of nourishing kidney and spleen, promoting diuresis, clearing away toxins, removing stasis, relieving pain and treating both symptoms and root causes; after being often drunk, the tea has the effects of clearing away dampness and toxins and dredging collateral channels of a patient with gout, and the tea has a good effect on treating of a gout disease and is low in recurrence rate after the patient is cured.

The invention provides a composition capable of reducing uric acid and dissolving uric acid crystals and tophus and application of the composition. The composition comprises a probiotic composition and prebiotics, wherein the probiotic composition is one or more of lactobacillus reuteri, lactobacillus fermentum, bacillus coagulans, lactobacillus rhamnosus, lactobacillus casei and lactobacillus plantarum, and the mass ratio of the probiotic composition to the prebiotics is (1-80):(1-80). The probiotic composition and the prebiotics are combined, the prepared compound bacterium powder can remarkably reduce blood uric acid of gout patients, and the crystal dissolving effect of the compound bacterium powder is verified through dual-energy CT for the first time.

The invention belongs to the technical field of a pharmaceutical co-crystal, and particularly relates to a novel febuxostat pharmaceutical co-crystal and a preparation method thereof. The space group of piracetam pharmaceutical co-crystal prepared by the invention is a monoclinic system, one isonicotinic acid molecule and two febuxostat molecules are combined together through a hydrogen bond respectively to form a basic structural unit of the febuxostat pharmaceutical co-crystal. A solvent selected in a preparation process of pharmaceutical co-crystal is ethyl acetate, and a solvent room temperature volatilization method is adopted. Due to a relatively low boiling point of the selected organic solvent, crystal is separated out during the process of solvent volatilization. The pharmaceutical co-crystal prepared by the invention inherits characteristics of traditional medicaments in preparing hyperuricemia of gout patients, and also has obvious change on solubility, stability and bioavailability.

The invention discloses a jelly capable of reducing uric acid and a preparation method thereof. The raw materials of the jelly comprises, by weight ratio, 25-40 parts of radix puerariae powder, 20-30parts of herba lophatheri powder, 15-20 parts of poria cocos powder, 13-20 parts of papaya powder, 22-30 parts of coix seeds, 15-25 parts of fructus crataegi, 5-10 parts of fructus lycii and 5-10 parts of water chestnuts, wherein the addition amount of probiotic lyophilized powder is 1*10<7> cfu / g-1*10<8> cfu / g. The jelly has a good curative effect on gout, rheumatoid arthritis and the like causedby high content of uric acid, can significantly reduce the content of uric acid in the body and relieve gout symptoms, and is applicable to patients suffering from gout.

The invention provides a Dai food capable of promoting uric acid metabolism and a preparation method thereof. The Dai food is composed of the following components in parts by weight: 50 to 100 parts of ampelopsis grossedentata leaf, 50 to 100 parts of root of kudzu vine, 60 to 100 parts of grosvenor momordica fruit, 20 to 30 parts of orange peel, 50 to 90 parts of purslane, 50 to 90 parts of mulberry fruit, 30 to 80 parts of lophatherum gracile, 30 to 90 parts of corn silk, 30 to 80 parts of cape jasmine, and 50 to 80 parts of radix astragali. The provided Dai food can reduce the uric acid, and is suitable for the people with high uric acid, gout patients and normal people. By drinking the Dai food, the uric acid can be reduced, the kidney can be targeted and protected; after regular application of the Dai food, the kidney can be strengthened, the uric acid is discharged, and the relapse of high uric acid symptom is inhibited. The Dai food is prepared from natural herbals, and does not any side or toxic effect, people do not need to avoid certain food, the active components in the Dai food can eliminate the toxin in the kidney, the taste of the Dai food is good, the Dai food can be drunk regularly and can meet the modern life requirements. Compared with similar products, the provided Dai food has the advantages of low cost, easy absorption, safety, reliability, no adverse reaction, and no sugar, and is suitable for any people.

A glass-state sosoloid of 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolylformic acid (TMX-67) and polyvinyl pyrrolidone for treating gout is disclosed. Its advantages are high stability and high dissolving speed.

The invention discloses a composite western medicine formula for treating gout. The composite western medicine is prepared from, by weight per granule, 0.2-0.5 g of sucralfate, 0.01-0.2 g of diclofenac sodium, 0.01-0.1 g of magnesium oxide, 0.1-0.3 g of benzbromarone and 0.2-1.5 g of chitin. According to the composite western medicine formula for treating the gout, the good gout treatment using effect is achieved; the activity of xanthine oxidase can be inhibited by using the benzbromarone, and therefore the concentration of uric acid in human blood is effectively lowered; by using the sucralfate, a layer of a protective film is formed to cover the ulcer surface, the effect of protecting the gastric mucosa is achieved, the using side effects of medicine on patients suffering from gastric ulcer and the like are effectively reduced, and meanwhile the effects of eliminating inflammation and relieving pain are obvious; by using the chitin, the effects of activating cells in a human body, preventing cell aging, promoting a newly-born cell band, adsorbing harmful heavy metal ions in the body, promoting human body detoxifying and the like can be achieved; gout patients can be effectively treated, and use is very convenient.

The invention relates to low-purine defatted soybean powder bread and a preparation method thereof. The low-purine defatted soybean powder bread is prepared from the following components in percentage by mass: 40-55% of flour, 10-20% of low-purine defatted soybean powder, 15-18% of water, 1.5-2.5% of soybean oil, 10-15% of white granulated sugar, 5-10% of egg liquid, 0.6% of yeast and 0.3% of salt. A preparation method of the low-purine defatted soybean powder comprises the following steps: mixing defatted soybean meal powder and water in a mass ratio of (1:6)-(1:12), wherein pH is 5.2; stirring and performing ultrasonic treatment; adding malt sprout powder accounting for 1.0-2.5% of total mass of the defatted soybean meal powder and water, and adding Ca<2+> and Mg<2+> and performing water bath treatment; performing adsorption and centrifugation to obtain low-purine defatted soybean milk; and performing spray drying on the low-purine defatted soybean milk to obtain the low-purine defatted soybean powder, wherein the purine content in every 100g of low-purine defatted soybean powder is 100-140mg. According to the invention, the flour and protein in the low-purine defatted soybean powder are complementary in nutrition, and the low-purine defatted soybean powder bread is suitable for gout patients.

The invention discloses an antalgic liniment for gout patients and belongs to medical preparations. The liniment is a liquid preparation prepared by soaking incised notopterygium, rhizoma corydalis, manchurian wildginger and borneol in a mass ratio of 10:10:8:10 in 95 percent of ethanol for 72 hours. The liniment has the following characteristics of: (1) achieving the effects of dispersing wind evil, relieving veins and arteries and dispelling wind, and penetrating joints to promote the restoration consciousness by adopting medicaments having acrid flavor and the effects of releasing, channeling, dispelling wind; (2) enhancing body surface blood circulation, making nutrient substance absorption and pathogenic factor resistance checkless, and having the effects of resisting virus and easing pain; (3) easing pain and diminishing inflammation, promoting blood circulation and removing obstruction in channels, running wind and dehumidifying, dissolving stasis and expelling cold, and meeting the theories of 'treating blood before treating wind, and wind extinguishing after blood circulation', and 'no thrombus, no pain'; (4) purifying body fluid, and removing wind cold and evil toxicity; (5) restoring bone joints, and recovering normal functions of swelled and distorted joints; and (6) regulating body functions, and improving immunocompetence. The antalgic liniment is suitable for adjuvant therapy of joint pain of the gout patients.

The invention discloses a preparation method of a Vaccinium dunalianum Wight extract. The preparation method comprises the following steps: taking tender leaves of Vaccinium dunalianum Wight, adding water, boiling for several minutes, then cooling, filtering, and taking the filtrate to obtain a thick juice; taking tender leaves of Vaccinium dunalianum Wight, adding water, boiling for several minutes, then cooling, filtering, and taking the filtrate to obtain a thin juice; proportionally taking the thick juice, adding the thick juice into the thin juice, stirring for several minutes, then leaving to stand, filtering, taking filter residues, and drying to obtain the Vaccinium dunalianum Wight extract. The preparation method of the Vaccinium dunalianum Wight extract is simple, low in cost and easy for large-scale production. The prepared Vaccinium dunalianum Wight extract has a very good curative effect on gout, can quickly relieve symptoms, has a very good function of preventing gout recurrence, is small in toxic and side effect, is suitable for various gout patients, has the effects of dispelling wind and removing obstruction in the meridians, tonifying qi and refreshing, can treat both symptoms and root causes of gout, also has a synergistic treatment function on kidney stone and hypertension, and is suitable for being taken by all gout patients for a long time.

The invention discloses a method for reducing purine content of soybean milk, and belongs to the technical field of food depurination. According to the soybean milk provided by the invention, soybeanswith purine content lowered are taken as a raw material, and macromolecular purine in a binding state is chosen to be hydrolyzed into small molecules according to different existence forms of the purine in soybeans, and then micromolecular purine is adsorbed and removed by an adsorbent. The method is high in feasibility and good in removal effect. The soybean milk disclosed by the invention is safe and non-toxic, high in purine removal rate, and low in nutrient loss, has no obvious change in mouth feel compared with common soybean milk, and can be used as a safe food for gout patients.

Disclosed are miracle fruit composite tea with a uric acid reducing effect and a preparation method thereof. The composite tea is prepared from, by weight, 10-25 parts of miracle fruit leaves, 2-6 parts of chicory, 5-15 parts of rhizoma smilacis glabrae, 15-30 parts of radix pueraiae, 1-4 parts of mulberry leaves and 5-15 parts of fructus crataegi. The preparation method of the composite tea comprises the following steps of 1, weighing all the raw materials by weight, and then sending all the raw materials into a mixer to be unevenly mixed to obtain a mixture; 2, separately bagging the mixturewith filter paper, and sealing openings to prepare tea bags, wherein the mixture in each bag weighs 30 g; 3, loading one tea bag and boiled water in a water boiling container separately, wherein eachtea bag is matched with 1,000 ml of boiled water; conducting decoction for 10 minutes, and drinking the tea after cooling. After long-term use, the obtained composite tea can eliminate the symptoms such as redness, heat, swelling and pain of the joints of gout patients, reduce the concentration of uric acid and have the advantage of the uric acid reducing effect.

The invention belongs to the field of biomedicine and particularly relates to a pharmaceutical composition with uric acid reduction and anti-fatigue functions. The pharmaceutical composition is prepared from raw materials as follows: marine fish oligopeptide, inulin, sodium citrate, potassium citrate and citric acid. Research shows that the composition in the invention has pharmacological functions of resisting fatigue and reducing uric acid, which further indicates that the composition in the invention can be applied to fatigue-induced gout patients.

The invention discloses a formula of a chitosan oligosaccharide and eucommia ulmoides male flower powder containing diet for a gout patient. The chitosan oligosaccharide and eucommia ulmoides male flower powder containing diet comprises the following components in parts by weight: 35-45 parts of marine fish collagen peptides, 15-25 parts of polydextrose, 2-3 parts of chitosan oligosaccharide, 5-10 parts of eucommia ulmoides male flower, 5-10 parts of zaocys dhumnades, 2-7 parts of earthworm proteins, 2-7 parts of tuckahoe powder, 5-8 parts of lily and 2-7 parts of Indian Iphigenia bulbs. According to the formula of the chitosan oligosaccharide and eucommia ulmoides male flower powder containing diet for the gout patient, all components of a drug can sufficiently take effects and have excellent treatment and healthcare effects through scientific compatibility.

The invention belongs to the technical field of pharmaceutical co-crystals and specifically relates to a novel febuxostat pharmaceutical co-crystal and a preparation method thereof, wherein the atom O of hydroxyl in a methanol molecule serves as a hydrogen bond donor and the atom N of thiazole in a febuxostat molecule serves as a hydrogen bond receptor; and the hydrogen bond donor and the hydrogen bond receptor form the hydrogen bond so as to form the basic structure unit of the febuxostat co-crystal. The preparation method of the febuxostat pharmaceutical co-crystal provided by the invention is a room-temperature solvent evaporation method. The pharmaceutical co-crystal prepared by the method provided by the invention inherits the feature of the traditional raw material capable of treating the hyperuricemia of a gout patient, and is obviously improved in solubility, stability and bioavailability.

The invention discloses a traditional Chinese medicine composition capable of resisting oxidation and also capable of reducing concentration of blood uric acid of a patient suffering from gout and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition capable of resisting oxidation and also capable of reducing concentration of blood uricacid of the patient suffering from gout comprises the following raw material components: Herba Cichorii, Radix Puerariae, Lignum Sappan, Rhizoma Polygoni Cuspidati, Herba Bidentis Bipinnatae, Semen Coicis, Folium Mori, Herba Taxilli, Rhizoma Atractylodis, schefflera octophylla, Malpighia glabra L., Herba clerodendranthi spicati, and Radix Angelicae Dahuricae. The invention further provides a preparation method of the traditional Chinese medicine. A traditional Chinese medicine formula of the invention takes a traditional Chinese medicine prescription theory as a guidance, is combined to modernscientific research, has the advantages of multi-target-point cooperation, capability of treating both principal and secondary aspect of disease, combination of traditional Chinese medicine and western medicines, safety and zero toxicity, not only can increase antioxidant ability of the patient suffering from the gout and improve clinical symptoms of the patient suffering from the gout, but alsohas effect of treating both principal and secondary aspect of disease.

The invention relates to a medicine for external application used for treating gout and a preparation method, the medicine for external application comprises the following traditional Chinese medicines: smallflower galinsoga flower, buckwheat root, philippine flemingia root, glabrousleaf pittosporum leaf and Paris polyphylla Smith; the above traditional Chinese medicines are respectively immersed in a boiled rice vinegar, and are inoculated to Acetobactersp. GLYSM66 CCTCC NO: M2011238, after fermenting through different fermentation times, and then a fermentation broth is blended to prepare the medicine. The medicine for external application has the function of dredging the channel and activating meridian, can rapidly reduce the uric acid level in blood of the gout patients, and has the advantages of fast pain relieving effect, good curative effect, low cost, no toxic and side effects and simple preparation method.

The invention discloses a pine nut protein peptide solid beverage rich in anthocyanin suitable for gout patients and a preparation method of the pine nut protein peptide solid beverage. The solid beverage contains the following components: microencapsulated pine nut protein peptide, blueberry lyophilized powder, mulberry lyophilized powder, strawberry lyophilized powder, raspberry lyophilized powder, fructus rubi lyophilized powder, cranberry lyophilized powder, red pitaya lyophilized powder, cherry lyophilized powder, purple grape lyophilized powder, black plum lyophilized powder, blackcurrant lyophilized powder, blood orange lyophilized powder, grapefruit lyophilized powder, red pomelo lyophilized powder, fig lyophilized powder, red beet lyophilized powder, purple cabbage lyophilized powder, fructus lycii lyophilized powder, purple carrot lyophilized powder, celery seed powder lyophilized powder and xylooligosaccharide. The solid beverage disclosed by the invention is rich in the anthocyanin and has high antioxidant property and high free radical scavenging ability; in addition, the solid beverage has the effects of diminishing inflammation, relieving pains, preventing and treating gout and improving acidic constitution; besides, by regulating spleen and kidney, the functions such as autonomous acid discharging of the kidney are restored and improved. The solid beverage has the advantages of easiness in carrying and brewing, good sensory character, obvious effects and wide application prospect.

The invention discloses a traditional Chinese medicine composition for conditioning gout and applications thereof. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-15 parts of mulberry leaf extract, 10-15 parts of wild chrysanthemum extract, 10-15 parts of kudzuvine root extract, 10-15 parts of glabrous greenbrier rhizome extract, 10-15 parts of Chinese yam extract and 40-50 parts of selenium-rich rice flour. The applications include: adding purified water to prepare an oral liquid or adding microcrystalline cellulose and magnesium stearateto prepare a powder. The composition has the beneficial effects that: the traditional Chinese medicine composition is prepared from common non-toxic plants and traditional Chinese medicine herbs withsmall toxicity to liver and kidney, so that a gout patient cannot have psychological burden and physical burden after long-term administration, and the composition has better conditioning and gout-relieving effects.

The present invention relates to the field of biomedicine, in particular to uricase or a homologous enzyme thereof as well as application of the uricase or the homologous enzyme. Through experiments,it is found that Escherichia coli Nissle 1917, which contains a novel non-homologous isomeric FAD-dependent urate oxidase, can be administered in a hyperuricemia rat model at a frequency of 3-5 days,and can still has ab effect of reducing blood uric acid of the rat model. The Escherichia coli Nissle 1917 is used, the purpose of using non-existing drug principles and avoiding daily use to alleviate hyperuricemia is achieved. The results show that Escherichia coli Nissle 1917 can be used for treating patients with hyperuricemia and gout.

The invention discloses a western medicine composition for treating gout and application of the western medicine composition. Active components of the western medicine composition include, by weight, 7-11 parts of tetrahydroserpentine, 5-9 parts of kaempferol and 8-12 parts of eugenol. Adult dosage is 0.4-0.48mg / kg / day. The western medicine composition which is prepared from tetrahydroserpentine, kaempferol and eugenol has advantages that by interaction of all components, gout symptom improvement and gout development delaying are remarkably and jointly realized, and accordingly healing of gout patients is facilitated, and the total clinical effective rate is 98-100%. The western medicine composition is low in dosage and has no evident adverse effects and toxic and side effects on human bodies, the problem of tolerance of gout treating medicines is effectively solved, and gout curative effects of the western medicine composition do not decline along with time.

The invention relates to a medicine, namely an external-bath Mongolian medicine for treating gout and a preparation method thereof, and provides an external-use Mongolian medicine for treating the gout. The external-bath Mongolian medicine is characterized by being prepared from the following crude drugs in parts by weight: 3 to 5 parts of radix salviae miltiorrhizae, 1 to 3 parts of flos carthami, 1 to 3 parts of semen plantaginis, 3 to 5 parts of fructus piperis longi and 3 to 5 parts of fructus gardeniae. The preparation method comprises the following steps: pulverizing the raw materials into coarse powder; completely soaking the coarse powder with 65 to 75 percent of ethanol; loading into a continuous refluxing extractor; carrying out refluxing extraction for 2 to 4 times by using 65 to 75 percent of ethanol at a temperature of 60 to 80 DEG C; merging extracting solutions; concentrating and drying to obtain an extract. The external-bath Mongolian medicine has the beneficial effects that the advantage of external bath of a Mongolian medicine is maintained, a toxic and side effect is avoided, the Mongolian medicine can be continuously used for a long time, an effect is taken quickly, and symptoms are continuously decreased until a disease is controlled; moreover, the preparation is simple, the cost is low, the use is convenient, and the Mongolian medicine brings relief to gout patients.